Diligence memo · auto-generated · as of July 2, 2026
Precision Genetics, Inc.
Precision Genetics, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Precision Genetics, Inc. operates in Pharmaceuticals, based in GREENVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Precision Genetics, Inc. has raised $1.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2024-05-30.
Most recent recorded round closed around 2024-05-30.
Valuation (modeled)modeled
Provath models Precision Genetics, Inc. at approximately $4.8M (range $560K–$16M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.87× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 20% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.